Assessment of the Cost-Effectiveness of Hypertension Management Strategies in Persons with Chronic Kidney Disease (CKD)[Centers for Disease Control and Prevention]
TTi was contracted by the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) of the Centers for Disease Control and Prevention (CDC) to update and expand an existing Chronic Kidney Disease (CKD) cost-effectiveness model in order to evaluate the cost effectiveness of blood pressure targets for CKD patients. A thorough and evaluative literature review of CKD progression and hypertension treatment in CKD and non-CKD populations was undertaken. The existing CKD disease model (developed in TreeAge as a discrete event simulation) was deconstructed; and model strengths, weaknesses, and areas for future improvements were documented and used to inform modifications to the model. Data inputs were integrated to update the CKD disease model in CKD progression functions, and a hypertension complications module and hypertension treatment protocol were implemented within the existing CKD disease model. The expanded model was validated with independent data sources (sources not employed in construction of the model). TTi finalized the external and internal validation protocol as the final step prior to conducting the cost-effectiveness analysis, convening an expert panel to review the model and modeled findings, and preparing a manuscript for journal publication. As a part of its contract with CDC, TTi also generated detailed administrative reports, including Summary and Monthly Reports.